clofazimine has been researched along with Electrolytes in 1 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Electrolytes: Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " All serious adverse events and adverse events of special interest (AESI), leading to a treatment change, or judged significant by a clinician, were systematically monitored and documented." | 1.72 | Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. ( Ahmed, S; Bastard, M; Franke, MF; Grium Tefera, D; Hewison, C; Holtzman, D; Huerga, H; Islam, S; Jacques Leblanc, G; Khan, PY; Khan, U; Kumsa, A; Lachenal, N; Leonovich, O; Mamsa, S; Manzur-Ul-Alam, M; Melikyan, N; Mitnick, CD; Myint, Z; Osso, E; Padayachee, S; Rafi Siddiqui, M; Rashitov, M; Rich, ML; Salahuddin, N; Salia, G; Sánchez, E; Serobyan, A; Seung, KJ; Varaine, F; Vetushko, D; Yeghiazaryan, L, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huerga, H | 1 |
| Khan, U | 1 |
| Bastard, M | 1 |
| Mitnick, CD | 1 |
| Lachenal, N | 1 |
| Khan, PY | 1 |
| Seung, KJ | 1 |
| Melikyan, N | 1 |
| Ahmed, S | 1 |
| Rich, ML | 1 |
| Varaine, F | 1 |
| Osso, E | 1 |
| Rashitov, M | 1 |
| Salahuddin, N | 1 |
| Salia, G | 1 |
| Sánchez, E | 1 |
| Serobyan, A | 1 |
| Rafi Siddiqui, M | 1 |
| Grium Tefera, D | 1 |
| Vetushko, D | 1 |
| Yeghiazaryan, L | 1 |
| Holtzman, D | 1 |
| Islam, S | 1 |
| Kumsa, A | 1 |
| Jacques Leblanc, G | 1 |
| Leonovich, O | 1 |
| Mamsa, S | 1 |
| Manzur-Ul-Alam, M | 1 |
| Myint, Z | 1 |
| Padayachee, S | 1 |
| Franke, MF | 1 |
| Hewison, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB With Regimens Containing Bedaquiline or Delamanid[NCT03259269] | 2,804 participants (Actual) | Observational | 2015-04-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for clofazimine and Electrolytes
| Article | Year |
|---|---|
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Topics: Antitubercular Agents; Clofazimine; Cohort Studies; Diarylquinolines; Electrolytes; Fluoroquinolones | 2022 |